Sequent Scientific Limited operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Sequent Scientific Limited with three other
companies in this sector in India:
Astrazeneca Pharma India Ltd
sales of 5.64 billion Indian Rupees [US$84.50 million]
of which 98%
Ind-Swift Laboratories Limited
(6.53 billion Indian Rupees [US$97.92 million]
Bliss GVS Pharma Limited
(5.47 billion Indian Rupees [US$81.98 million]
of which 100%
was Pharmaceutical Business).
During the year ended March of 2016, sales at
Sequent Scientific Limited were 6.34 billion Indian Rupees (US$95.11 million).
increase of 43.2%
versus 2015, when the company's sales were 4.43 billion Indian Rupees.
Sales of Pharmaceuticals saw an increase
44.8% in 2016, from
4.33 billion Indian Rupees to 6.27 billion Indian Rupees.
Not all segments of Sequent Scientific Limited experienced an increase in sales in 2016:
sales of Analytical Services fell 25.5% to 78.86 million Indian Rupees.
(However, this segment's sales were only a very small portion of the company's overall sales).